|
1
|
Yu W, Zhang R, Zhang A, Mei Y. Deciphering the Functions of Raphe-Hippocampal Serotonergic and Glutamatergic Circuits and Their Deficits in Alzheimer's Disease. Int J Mol Sci 2025; 26:1234. [PMID: 39941002 PMCID: PMC11818420 DOI: 10.3390/ijms26031234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2025] [Revised: 01/28/2025] [Accepted: 01/29/2025] [Indexed: 02/16/2025] Open
Abstract
Subcortical innervation of the hippocampus by the raphe nucleus is essential for emotional and cognitive control. The two major afferents from raphe to hippocampus originate from serotonergic and glutamatergic neurons, of which the serotonergic control of hippocampal inhibitory network, theta activity, and synaptic plasticity have been extensively explored in the growing body of literature, whereas those of glutamatergic circuits have received little attention. Notably, both serotonergic and glutamatergic circuits between raphe and hippocampus are disrupted in Alzheimer's disease (AD), which may contribute to initiation and progression of behavioral and psychological symptoms of dementia. Thus, deciphering the mechanism underlying abnormal raphe-hippocampal circuits in AD is crucial to prevent dementia-associated emotional and cognitive symptoms. In this review, we summarize the anatomical, neurochemical, and electrophysiological diversity of raphe nuclei as well as the architecture of raphe-hippocampal circuitry. We then elucidate subcortical control of hippocampal activity by raphe nuclei and their role in regulation of emotion and cognition. Additionally, we present an overview of disrupted raphe-hippocampal circuits in AD pathogenesis and analyze the available therapies that can potentially be used clinically to alleviate the neuropsychiatric symptoms and cognitive decline in AD course.
Collapse
Affiliation(s)
| | | | | | - Yufei Mei
- Hubei Clinical Research Center for Alzheimer’s Disease, Brain Science and Advanced Technology Institute, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China
| |
Collapse
|
|
2
|
Leisgang Osse AM, Kinney JW, Cummings JL. The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization. ALZHEIMER'S & DEMENTIA (NEW YORK, N. Y.) 2025; 11:e70050. [PMID: 39935614 PMCID: PMC11812129 DOI: 10.1002/trc2.70050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/28/2024] [Revised: 01/03/2025] [Accepted: 01/06/2025] [Indexed: 02/13/2025]
Abstract
Biomarkers are vital to Alzheimer's disease (AD) drug development and clinical trials, and will have an increasing role in clinical care. In this narrative review, we demonstrate the use of the National Institutes on Aging/Alzheimer's Association (NIA/AA) Common Alzheimer's Disease Research Ontology (CADRO) system for the categorization of biomarkers based on the primary mechanism on which they report. We show that biomarkers are available (in various levels of validation) for all CADRO processes. Application of the CADRO system demonstrates gaps in the field where novel biomarkers are needed for specific aspects of the disease, and assays to detect and measure biological changes, in individuals with symptomatic or preclinical AD. We demonstrate the CADRO system as a means of categorizing established and candidate AD biomarkers, showing the feasibility and practicality of the system. CADRO can assist with biomarker selection for AD clinical trials and drug development, and may eventually be applied to implementing biomarkers in patient care. Highlights The Common Alzheimer's Disease Research Ontology (CADRO) system can be used to categorize biomarkers for drug development.We demonstrate the use of CADRO with Alzheimer's disease (AD) biomarkers.We identified AD biomarkers in each of the CADRO categories.CADRO can be incorporated into current AD drug development and clinical trial systems.
Collapse
Affiliation(s)
- Amanda M. Leisgang Osse
- Department of Brain Health, Kirk Kerkorian School of MedicineUniversity of Nevada Las Vegas (UNLV)Las VegasNevadaUSA
| | - Jefferson W. Kinney
- Department of Brain Health, Kirk Kerkorian School of MedicineUniversity of Nevada Las Vegas (UNLV)Las VegasNevadaUSA
| | - Jeffrey L. Cummings
- Department of Brain Health, Kirk Kerkorian School of MedicineUniversity of Nevada Las Vegas (UNLV)Las VegasNevadaUSA
| |
Collapse
|
|
3
|
Xing C, Chen H, Bi W, Lei T, Hang Z, Du H. Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases. Int J Mol Sci 2024; 25:13446. [PMID: 39769209 PMCID: PMC11679250 DOI: 10.3390/ijms252413446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2024] [Revised: 12/07/2024] [Accepted: 12/13/2024] [Indexed: 01/11/2025] Open
Abstract
There is increasing interest in the potential therapeutic role of 5-HT (serotonin) in the treatment of neurodegenerative diseases, which are characterized by the progressive degeneration and death of nerve cells. 5-HT is a vital neurotransmitter that plays a central role in regulating mood, cognition, and various physiological processes in the body. Disruptions in the 5-HT system have been linked to several neurological and psychiatric disorders, making it an attractive target for therapeutic intervention. Although the exact causes of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are not fully understood, researchers believe that regulating the 5-HT system could help alleviate symptoms and potentially slow the progression of these diseases. Here, we delve into the potential of harnessing 5-HT as a therapeutic target for the treatment of neurodegenerative diseases. It is important to note that the current clinical drugs targeting 5-HT are still limited in the treatment of these complex diseases. Therefore, further research and clinical trials are needed to evaluate the feasibility and effectiveness of its clinical application.
Collapse
Affiliation(s)
- Cencan Xing
- Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China; (C.X.); (H.C.); (W.B.); (Z.H.)
- School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China;
| | - Hongyu Chen
- Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China; (C.X.); (H.C.); (W.B.); (Z.H.)
- School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China;
| | - Wangyu Bi
- Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China; (C.X.); (H.C.); (W.B.); (Z.H.)
- School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China;
| | - Tong Lei
- School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China;
| | - Zhongci Hang
- Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China; (C.X.); (H.C.); (W.B.); (Z.H.)
- School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China;
| | - Hongwu Du
- Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China; (C.X.); (H.C.); (W.B.); (Z.H.)
- School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China;
| |
Collapse
|
|
4
|
Crawford JL, Berry AS. Examining resilience to Alzheimer's disease through the lens of monoaminergic neuromodulator systems. Trends Neurosci 2024; 47:892-903. [PMID: 39368845 PMCID: PMC11563896 DOI: 10.1016/j.tins.2024.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2024] [Revised: 08/15/2024] [Accepted: 09/16/2024] [Indexed: 10/07/2024]
Abstract
The monoaminergic nuclei are thought to be some of the earliest sites of Alzheimer's disease (AD) pathology in the brain, with tau-containing pretangles appearing in these nuclei decades before the onset of clinical impairments. It has increasingly been recognized that monoamine systems represent a critical target of investigation towards understanding the progression of AD and designing early detection and treatment approaches. This review synthesizes evidence across animal studies, human neuropathology, and state-of-the-art neuroimaging and daily life assessment methods in humans, which demonstrate robust relationships between monoamine systems and AD pathophysiology and behavior. Further, the review highlights the promise of multimethod, multisystem approaches to studying monoaminergic mechanisms of resilience to AD pathology.
Collapse
Affiliation(s)
| | - Anne S Berry
- Department of Psychology, Brandeis University, Waltham, MA, USA.
| |
Collapse
|
|
5
|
Yamamoto K, Tsuji M, Oguchi T, Momma Y, Ohashi H, Ito N, Nohara T, Nakanishi T, Ishida A, Hosonuma M, Nishikawa T, Murakami H, Kiuchi Y. Comparison of Protective Effects of Antidepressants Mediated by Serotonin Receptor in Aβ-Oligomer-Induced Neurotoxicity. Biomedicines 2024; 12:1158. [PMID: 38927365 PMCID: PMC11200737 DOI: 10.3390/biomedicines12061158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Revised: 05/16/2024] [Accepted: 05/20/2024] [Indexed: 06/28/2024] Open
Abstract
Amyloid β-peptide (Aβ) synthesis and deposition are the primary factors underlying the pathophysiology of Alzheimer's disease (AD). Aβ oligomer (Aβo) exerts its neurotoxic effects by inducing oxidative stress and lesions by adhering to cellular membranes. Though several antidepressants have been investigated as neuroprotective agents in AD, a detailed comparison of their neuroprotection against Aβo-induced neurotoxicity is lacking. Here, we aimed to elucidate the neuroprotective effects of clinically prescribed selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants at the cellular level and establish the underlying mechanisms for their potential clinical applications. Therefore, we compared the neuroprotective effects of three antidepressants, fluoxetine (Flx), duloxetine (Dlx), and mirtazapine (Mir), by their ability to prevent oxidative stress-induced cell damage, using SH-SY5Y cells, by evaluating cell viability, generation of reactive oxygen species (ROS) and mitochondrial ROS, and peroxidation of cell membrane phospholipids. These antidepressants exhibited potent antioxidant activity (Dlx > Mir > Flx) and improved cell viability. Furthermore, pretreatment with a 5-hydroxytryptamine 1A (5-HT1A) antagonist suppressed their effects, suggesting that the 5-HT1A receptor is involved in the antioxidant mechanism of the antidepressants' neuroprotection. These findings suggest the beneficial effects of antidepressant treatment in AD through the prevention of Aβ-induced oxidative stress.
Collapse
Affiliation(s)
- Ken Yamamoto
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Mayumi Tsuji
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Tatsunori Oguchi
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Yutaro Momma
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Hideaki Ohashi
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Naohito Ito
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Tetsuhito Nohara
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Tatsuya Nakanishi
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Atsushi Ishida
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Masahiro Hosonuma
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Toru Nishikawa
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Hidetomo Murakami
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Yuji Kiuchi
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| |
Collapse
|
|
6
|
Fakih N, Fakhoury M. Alzheimer Disease-Link With Major Depressive Disorder and Efficacy of Antidepressants in Modifying its Trajectory. J Psychiatr Pract 2024; 30:181-191. [PMID: 38819242 DOI: 10.1097/pra.0000000000000779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/01/2024]
Abstract
Alzheimer disease (AD) is a devastating neurodegenerative disorder that affects millions of individuals worldwide, with no effective cure. The main symptoms include learning and memory loss, and the inability to carry out the simplest tasks, significantly affecting patients' quality of life. Over the past few years, tremendous progress has been made in research demonstrating a link between AD and major depressive disorder (MDD). Evidence suggests that MDD is commonly associated with AD and that it can serve as a precipitating factor for this disease. Antidepressants such as selective serotonin reuptake inhibitors, which are the first line of treatment for MDD, have shown great promise in the treatment of depression in AD, although their effectiveness remains controversial. The goal of this review is to summarize current knowledge regarding the association between AD, MDD, and antidepressant treatment. It first provides an overview of the interaction between AD and MDD at the level of genes, brain regions, neurotransmitter systems, and neuroinflammatory markers. The review then presents current evidence regarding the effectiveness of various antidepressants for AD-related pathophysiology and then finally discusses current limitations, challenges, and future directions.
Collapse
Affiliation(s)
- Nour Fakih
- Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon
| | | |
Collapse
|
|
7
|
Tian Y, Ye Q, Qiao J, Wang L, Dai Y, Wen H, Dou Z. A causal relationship between panic disorder and risk of alzheimer disease: a two-sample mendelian randomization analysis. BMC Psychiatry 2024; 24:178. [PMID: 38439042 PMCID: PMC10913557 DOI: 10.1186/s12888-024-05624-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Accepted: 02/19/2024] [Indexed: 03/06/2024] Open
Abstract
BACKGROUND Observational studies have suggested a link between panic disorder (PD) and Alzheimer disease (AD). This study aimed to identify the underlying association of PD with the risk of AD using Mendelian randomization. METHODS Genetic instrumental variables (IVs) were retrieved in the genome-wide association study between PD and AD. Then, five different models, namely inverse variance weighting (IVW), weighted median, weighted mode, MR-Egger and MR-robust adjusted profile scores (MR-RAPS), were used for MR Analysis. Finally, the heterogeneity and pleiotropy of identified IVs were verified by multiple sensitivity tests. RESULTS The Cochran's Q test based on MR Egger and IVW showed that no evidence of heterogeneity was found in the effects of instrumental variables, so a fixed-effect model was used. IVW analysis (OR 1.000479, 95% CI [1.000147056, 1.000811539], p = 0.005) indicated that PD was associated with an increased risk of AD, and a causal association existed between them. Meanwhile, weighted median (OR 1.000513373, 95% CI [1.000052145, 1.000974814], p = 0.029) and MR-RAPS (OR 1.000510118, 95% CI [1.000148046, 1.00087232], p = 0.006) also showed the similar findings. In addition, extensive sensitivity analyses confirmed the robustness and accuracy of these results. CONCLUSION This investigation provides evidence of a potential causal relationship between PD and the increased risk of AD. Based on our MR results, when diagnosing and treating patients with PD, clinicians should pay more attention to their AD-related symptoms to choose therapeutic measures or minimize comorbidities. Furthermore, the development of drugs that improve both PD and AD may better treat patients with these comorbidities.
Collapse
Affiliation(s)
- Yueqin Tian
- Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, No. 600, Tianhe Road, 510630, Guangzhou, Guangdong, China
| | - Qiuping Ye
- Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, No. 600, Tianhe Road, 510630, Guangzhou, Guangdong, China
| | - Jia Qiao
- Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, No. 600, Tianhe Road, 510630, Guangzhou, Guangdong, China
| | - Lian Wang
- Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, No. 600, Tianhe Road, 510630, Guangzhou, Guangdong, China
| | - Yong Dai
- Clinical Medical College of Acupuncture, Guangzhou University of Chinese Medicine, 510006, Guangzhou, China
| | - Hongmei Wen
- Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, No. 600, Tianhe Road, 510630, Guangzhou, Guangdong, China.
| | - Zulin Dou
- Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, No. 600, Tianhe Road, 510630, Guangzhou, Guangdong, China.
| |
Collapse
|